In in vitro and in vivo preclinical studies, ficerafusp alfa + a KRAS-G12C inhibitor (G12Ci) was shown to be more effective than G12Ci alone, with G12Ci-resistant lung cancer cells remaining ...

When Roy Bradley was told he had cancer in his lungs and liver, his first thought was he couldn't face chemotherapy and ...

This retrospective analysis included 102 patients with advanced RCC treated with either cabozantinib + nivolumab or lenvatinib + pembrolizumab as first-line therapy at Tokyo Women's Medical University ...

Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25 - Interim datasets from GALAXIES H&N-202 and TIG-006 HNSCC with ~200 patients anticipated in 2025 - Cash ...

Adding pembrolizumab (Keytruda), before and after surgery, to standard adjuvant therapy for locally advanced head and neck ...

Summit Therapeutics highlights China approval of Akeso's ivonescimab for NSCLC, with enrollment ongoing for Phase 3 HARMONi-7 ...

Pembrolizumab combo before/after surgery and radiation significantly improved event-free survival in resectable advanced head ...

The addition of neoadjuvant and adjuvant pembrolizumab to standard of care significantly improved outcomes for certain ...

The combination of the PARP inhibitor olaparib and the PD-1 inhibitor pembrolizumab showed initial antitumor activity with no new safety signals in a molecularly matched, tumor-agnostic trial, ...

Summit Therapeutics Inc. is currently enrolling patients in the Harmoni-7 study, a multiregional Phase III clinical trial ...

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during ...

An immunotherapy treatment could ‘change the world’ for newly diagnosed head and neck cancer patients by giving them an extra ...